Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16904015 | 0.87 | — | — | |
| SCHEMBL10578443 | 0.87 | — | — | |
| SCHEMBL10836588 | 0.87 | ALDH1A1 (0.43) | ALDH1A1TRPA1CYP2C19TSHRSOAT1 | |
| SCHEMBL10836711 | 0.83 | — | — | |
| SCHEMBL8147946 | 0.81 | ALDH1A1 (0.36) | ALDH1A1TRPA1CYP2C19L3MBTL1TSHR | |
| SCHEMBL9569864 | 0.80 | TRPA1 (0.33) | ALDH1A1TRPA1CYP2C19L3MBTL1TSHR | |
| SCHEMBL11055999 | 0.79 | — | — | |
| SCHEMBL11602769 | 0.78 | — | — | |
| SCHEMBL8813399 | 0.78 | — | — | |
| SCHEMBL291551 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220416300-A1 | Flame Retardants For Battery Electrolytes | ALBEMARLE CORPORATION | 2022-12-29 | — | — | US | claimed |
| EP-4062480-A1 | FLAME RETARDANTS FOR BATTERY ELECTROLYTES | ALBEMARLE CORPORATION (US) | 2022-09-28 | — | — | EP | claimed |
| CN-114762175-A | Flame retardant for battery electrolytes | 雅宝公司 | 2022-07-15 | — | — | CN | claimed |
| WO-2021101924-A1 | FLAME RETARDANTS FOR BATTERY ELECTROLYTES | ALBEMARLE CORPORATION (US) | 2021-05-27 | — | — | WO | claimed |
| EP-2727915-B1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS INC (US) | 2016-04-13 | — | — | EP | claimed |
| EP-2727915-A1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | Concert Pharmaceuticals Inc. (US) | 2014-05-07 | — | — | EP | claimed |
| EP-4604951-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | AMIRA THERAPEUTICS, S.L. (ES) | 2025-08-27 | — | — | EP | disclosed |
| EP-4419513-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2025-08-27 | — | — | EP | disclosed |
| US-12384800-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2025-08-12 | — | — | US | disclosed |
| US-20250243174-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2025-07-31 | — | — | US | disclosed |
| WO-2025077996-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS | PHARMA MAR, S.A. (ES) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025050647-A1 | IONIZABLE CATIONIC LIPID COMPOUNDS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 晟迪生物医药(苏州)有限公司 | 2025-03-13 | — | — | WO | disclosed |
| US-12215100-B2 | Anticancer compounds | PHARMA MAR, S.A. (ES) | 2025-02-04 | — | — | US | disclosed |
| WO-2009035652-A1 | SYNTHESIS OF DEUTERATED CATECHOLS AND BENZO[D][1,3] DIOXOLES AND DERIVATIVES THEREOF | CONCERT PHARMACEUTICALS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| EP-2032551-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-03-11 | — | — | EP | disclosed |
| WO-2009017671-A1 | SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2007144423-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2007-12-21 | — | — | WO | disclosed |
| CN-1992420-A | Rechargeable lithium battery | SAMSUNG SDI CO LTD (KR) | 2007-07-04 | — | — | CN | disclosed |
| US-6041157-A | Environmentally sensitive compositions of matter based on 3H-fluoren-3-ylidenes and process for making same | GOETZ FREDERICK JAMES (US) | 2000-03-21 | — | — | US | disclosed |
| US-5622944-A | MODIFIED 17-HYDROXY STEROL; TRANSDERMAL ELECTROTRANSPORT ENHANCEMENT | AFFYMAX TECHNOLOGIES N.V. (GB) | 1997-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384800-B2 | Antitumoral compounds | TP53, TOP1, MCL1 | ALDH1A1 144/4885TRPA1 4677/4885CYP2C19 1491/4885 |
| US-20250243174-A1 | ANTITUMORAL COMPOUNDS | MCL1, XPOT, GZMB | ALDH1A1 318/4885TRPA1 4444/4885CYP2C19 1582/4885 |
| US-12215100-B2 | Anticancer compounds | TP53, MCL1, MYC | ALDH1A1 795/4885TRPA1 3956/4885CYP2C19 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.